Women's College Hospital
Toronto, Ontario, M5S 1B2, Canada
NCT Number: NCT03978780
Regional anaesthesia combined with general anaesthesia has become common in the perioperative management of breast cancer surgery patients. Regional techniques have been recognised to provide excellent post-operative analgesia. It enhances multi-modal analgesia regimes while being opioid sparing, reducing incidence of post-operative nausea and vomiting and allowing earlier mobilisation/discharge and improving treatment success. Therefore identifying the correct regional anaesthetic technique for this group of patients is important in providing optimum peri-operative care.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Not applicable
Toronto, Ontario, M5S 1B2, Canada
The ultrasound-guided erector spinae plane (ESP) block has been recently described for the successful management of thoracic neuropathic pain. The erector spinae muscle is formed by the spinalis, longissimus thoracis, and iliocostalis muscles that run vertically in the back. The ESP block is performed by depositing the local anaesthetic in the fascial plane, deep to the erector spinae muscle, at the tip of the transverse process of the vertebra. Indirect access to the paravertebral space is gained providing analgesia without the risk of needle injury to structures in close proximity. Cadaveric studies have shown both ventral and dorsal rami of thoracic spinal nerves are affected when local anaesthetic is injected deep to the erector spinae muscle. The erector spinae muscle extends along the thoracolumbar spine allowing extensive cranio-caudal spread. The ventral ramus (intercostal nerve) is divided into the anterior and lateral branches. Its terminal branches provide the sensory innervation of the entire anterolateral wall. The dorsal ramus is divided into 2 terminal branches and it gives the sensory innervation to the posterior wall. Anterior spread of the local anaesthetic to the paravertebral space through the costotransverse foramina and the intertransverse complex provides both visceral and somatic analgesia.
While recent evidence supports statistically significant reductions in pain and opioid consumption among patients who receive an ESP block compared to systemic analgesia alone, the clinical significance of these differences are questionable the effect of ESP block on the patients' quality of recovery following ambulatory breast cancer surgery remains unclear.
Therefore, our objective is to determine whether or not the addition of an ESP block provides both superior analgesia and quality of recovery in patients undergoing ambulatory breast cancer surgery compared to systemic analgesia alone. We hypothesis that patients who received a preoperative ESP block will afford superior postoperative analgesia and improve the quality of recovery over the first 24 hours following surgery compared to those who receive a sham block for their ambulatory breast cancer surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block under ultrasound guidance to stimulate a real block procedure.
Time frame: 24 hours postoperatively
Following breast surgery, measured as an area under the curve (AUC) of rest pain scores VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable
Time frame: 24 hours post-surgery
Quality of recovery at 24 hours: questionnaire (0-10, where 0 = none of the time [poor] and 10 = all of the time [excellent])
Time frame: 0, 6, 12, 18, 24 and 48 hours post-operatively
VAS scale where 0 corresponds to no pain, and 10 corresponds to worst pain imaginable
Time frame: During the procedure
Cumulative oral morphine equivalent after surgery
Time frame: 12,24,48 hours, 7 days postoperative
Cumulative oral morphine equivalent after surgery
Time frame: From end of surgical procedure to 24 hours after surgery
How fast is the recovery is-expressed in minutes
Time frame: End of surgical procedure to 48 hours after surgery
Risk of opioid-related side effects(nausea, vomiting, pruritis)
Time frame: 3 months post operatively
Satisfaction with pain management. Is prescribed pain medication enough?
Time frame: End of surgical procedure to 48 hours after surgery
bruising at injection site, numbness over lateral chest, weakness of shoulder or arm, pain/swelling at injection site
Contact information is provided by the study sponsor or research team.
Women's College Hospital
Other
Quality of Recovery Scores Following Erector Spinae Block vs. Sham Block in Ambulatory Breast Cancer Surgery: A Randomised Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07246720
Agnosia, Breast Cancer
Zonguldak, Kozlu, Turkey (Türkiye)
View Trial DetailsNCT03653988
Anesthesia, Breast Cancer
Iowa City, Iowa, United States
View Trial DetailsNCT07619534
Breast Cancer, Breast Carcinoma
Bethesda, Maryland, United States
View Trial DetailsNCT07737132
Breast Cancer, Breast Diseases
View Trial Details